Search

Meet a few of our brave and determined young patients who are thriving after receiving treatment at MSK.

… Friday, October 1, 2021 Ending cancer treatment is an exciting yet tricky transition for adolescents and young adults. But MSK keeps a close eye on these survivors as their physical, emotional, and social needs change over time. There are three survivorship clinics — each tailored to a specific age group

Learn more about the first facility in the world devoted to the specific needs of colorectal cancer patients under the age of 50.

… Monday, March 8, 2021 Summary A troubling rise in colorectal cancer among younger adults has led experts to advise issuing new guidelines that lower the recommended age when people should begin colorectal screenings from 50 to 45. In 2018, MSK established the first facility in the world devoted to the

Obtenga más información sobre el primer centro en el mundo dedicado a las necesidades específicas de los pacientes con cáncer colorrectal menores de 50 años.

… Monday, March 8, 2021 Resumen Un aumento preocupante de casos de cáncer colorrectal entre los adultos más jóvenes ha llevado a los expertos a sugerir que se publiquen nuevas pautas que reduzcan la edad recomendada en que las personas deben comenzar a hacerse las pruebas de detección colorrectal de los

Memorial Sloan Kettering attained Magnet recognition for the second time, a testament to our continued dedication to high-quality nursing practice.

… Wednesday, November 25, 2020 VIDEO | 03:09 2020 MSK Nurses Magnet Recognition Video Details On November 23, 2020, Memorial Sloan Kettering (MSK) attained Magnet recognition for the second time, a testament to our continued dedication to high-quality nursing practice. The American Nurses Credentialing

MSK’s Convocation and the Gerstner Sloan Kettering Graduate School of Biomedical Sciences Commencement celebrate the achievements of young scientists.

… Wednesday, June 10, 2015 Ruth Anne Franklin (left), Ming Li, Myoungjoo Kim Graduates Ruth Anne Franklin (left) and Myoungjoo Kim with their mentor, immunologist Ming Li 2015 graduates Graduates of GSK and a joint program between Weill Cornell Medical College and the Sloan Kettering Institute with their

Memorial Sloan Kettering has named three winners of this year’s Paul Marks Prize for Cancer Research, an award that recognizes promising investigators.

… Friday, November 8, 2019 Summary The Paul Marks Prize for Cancer Research, first awarded in 2001, recognizes promising scientists who have made important contributions to the study of cancer. Memorial Sloan Kettering has named three investigators as the recipients of this year’s Paul Marks Prize for

Discover some of the most exciting research that Memorial Sloan Kettering scientists are pursuing in the fight against cancer.

… Tuesday, May 10, 2016 Summary Memorial Sloan Kettering scientists believe there are many reasons to be hopeful about the future of cancer care and research. Here, we take a look at five promising advances that are transforming the way we think about cancer and delivering new treatment tactics. Highlights

At Memorial Sloan Kettering, as the genetics revolution continues to flourish, discoveries made in the laboratory are increasingly producing real-world benefits for cancer patients.

… Wednesday, October 1, 2008 Summary At Memorial Sloan Kettering, as the genetics revolution continues to flourish, discoveries made in the laboratory are increasingly producing real-world benefits for cancer patients. As the genetics revolution continues to flourish, discoveries made in the laboratory

A new report says that ovarian cancer research is improving, but more needs to be done, especially with regards to screening at an early stage. Also, where patients receive care makes a big difference in their outcome.

… Friday, March 4, 2016 Summary A new report from the Institutes of Medicine says that ovarian cancer research is improving, but more needs to be done, especially with regards to screening for signs of ovarian cancer  at an early stage. The report also points out that where patients receive care makes

A paper from MSK researchers reports that resistance to sotorasib, a new targeted drug for lung cancer, can be caused by many different molecular changes.

… Thursday, November 11, 2021 The recent accelerated approval of sotorasib (Lumakras TM ) was considered significant because the drug obstructs a cancer-causing protein that for decades scientists thought was “undruggable.” Sotorasib received accelerated approved from the US Food and Drug Administration